User profiles for Leland Shapiro
Leland ShapiroVerified email at cuanschutz.edu Cited by 7076 |
A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses.
AE Chernoff, EV Granowitz, L Shapiro… - … (Baltimore, Md.: 1950 …, 1995 - journals.aai.org
In vitro, IL-10 inhibits T cell proliferation and LPS-induced monocyte production of IL-1, TNF-alpha,
IL-6, and IL-8. We studied the safety and immunomodulatory effects of IL-10 …
IL-6, and IL-8. We studied the safety and immunomodulatory effects of IL-10 …
Plasma levels of IL-1β, TNFα and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients
BJG Pereira, L Shapiro, AJ King, ME Falagas… - Kidney international, 1994 - Elsevier
… SHAPIRO L, CLARK BD, ORENCOLE SF, POUTSIAKA DD, GRAN0wITZ EV, DINARELLO
CA: Detection of tumor necrosis factor soluble receptor p55 in blood samples from healthy …
CA: Detection of tumor necrosis factor soluble receptor p55 in blood samples from healthy …
Overview of interleukin-18: more than an interferon-γ inducing factor
Initially described in 1989 as interferon-γ (IFN-γ) inducing factor (IGIF), interleukin-18 (IL-18)
is a novel proinflammatory cytokine that is clearly more than an inducer of IFN-γ The …
is a novel proinflammatory cytokine that is clearly more than an inducer of IFN-γ The …
Osmotic regulation of cytokine synthesis in vitro.
L Shapiro, CA Dinarello - Proceedings of the National …, 1995 - National Acad Sciences
These studies were undertaken to investigate the therapeutic mechanism of saturated solutions
of KI, used to treat infectious and inflammatory diseases. The addition of 12-50 mM KI to …
of KI, used to treat infectious and inflammatory diseases. The addition of 12-50 mM KI to …
Interleukin-1 induces interleukin-8 secretion from endothelial cells by a juxtacrine mechanism
…, C Farnarier, S Kaplanski, R Porat, L Shapiro… - 1994 - ashpublications.org
Inflammation is characterized by migration of neutrophils through the endothelium, and the
chemokine interleukin-8 (IL-8) appears to be involved. We asked whether adherence of cells …
chemokine interleukin-8 (IL-8) appears to be involved. We asked whether adherence of cells …
Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes
Rationale: Among patients with nontuberculous mycobacterial lung disease is a subset of
previously healthy women with a slender body morphotype, often with scoliosis and/or pectus …
previously healthy women with a slender body morphotype, often with scoliosis and/or pectus …
Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial
…, S Shanmugasundaram, S Bangera, L Shapiro… - The Journal of heart and …, 2010 - Elsevier
BACKGROUND: Pulmonary arterial hypertension (PAH) remains a poorly understood and
frequently lethal disease with few treatment options. METHODS: We conducted a placebo-…
frequently lethal disease with few treatment options. METHODS: We conducted a placebo-…
α-1-Antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood
…, ED Chan, CA Dinarello, L Shapiro - Journal of Leucocyte …, 2009 - academic.oup.com
Several observations suggest endogenous suppressors of inflammatory mediators are present
in human blood. α-1-Antitrypsin (AAT) is the most abundant serine protease inhibitor in …
in human blood. α-1-Antitrypsin (AAT) is the most abundant serine protease inhibitor in …
α1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice
Human pancreatic islet transplantation offers diabetic patients tight glucose control but has
low graft survival rates. The immunosuppressive drugs that are administered to graft …
low graft survival rates. The immunosuppressive drugs that are administered to graft …
α1-antitrypsin monotherapy prolongs islet allograft survival in mice
Islet transplantation for type 1 diabetic patients shows promising results with the use of
nondiabetogenic immunosuppressive therapy. However, in addition to compromising the immune …
nondiabetogenic immunosuppressive therapy. However, in addition to compromising the immune …